Trade BMEA stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Biomea Fusion, Inc. (BMEA) is trading at US$1.26, down 7.35% today as of Oct 13, 16:00 EDT. The company has a market capitalisation of US$99.3M. Over the past 52 weeks, BMEA has traded between US$0.87 and US$2.24. On Syfe you can trade BMEA with $0 commission and add it to your watchlist.
| Previous close | US$1.36 |
|---|---|
| Market cap | US$99.3M |
| 52-week range | US$0.87 – US$2.24 |
| Volume | 4.68M |
| Exchange | US |
Biomea Fusion, Inc.
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in San Carlos, CA.
Year: 2021
Sector Update: Healthcare Stocks Softer Late Afternoon
Aug 24, 7:47 PM · MT Newswires
Biomea Shares Rise After Completing Enrollment in Diabetes Trial
Aug 24, 6:47 PM · MT Newswires
Biomea Fusion, Inc. (BMEA) stock is trading at US$1.26, -7.35% from the previous close of US$1.36.
The market cap for Biomea Fusion, Inc. (BMEA) stock is approximately US$99.3M.
The 52-week high for Biomea Fusion, Inc. (BMEA) stock is US$2.24.
The 52-week low for Biomea Fusion, Inc. (BMEA) stock is US$0.87.
Biomea Fusion, Inc. (BMEA) does not currently pay a dividend.
Stay on top of BMEA
Price moves, news and earnings — straight to your inbox.
Snapshot
Popular Stocks in Singapore
